Get alerts on this situation

We’ll email you as it develops, and you can follow the whole thread from day one.

Unsubscribe anytime.

[SITUATION] · [ACTIVE]

2 clusters · 19 sources · 10 days · First seen 9 days ago · Last updated about 7 hours ago

Categories: HEALTH

Bundibugyo Ebola vaccine trials

Entities: University of Oxford · Coalition for Epidemic Preparedness Innovations · Bundibugyo Ebola virus · Democratic Republic of the Congo · mRNA-1469

Overview

In late July 2026, the Oxford Vaccine Group administered the first dose of its ChAdOx1 BDBV vaccine to a healthy British volunteer, marking the start of a Phase 1 safety and immunogenicity study. The adenoviral‑vector vaccine targets the Bundibugyo strain of Ebola, for which no licensed vaccine exists, and is backed by 600,000 doses produced by the Serum Institute of India in anticipation of successful results. The trial follows a worsening Bundibugyo Ebola outbreak in the Democratic Republic of the Congo, declared a public‑health emergency with over 2,500 confirmed cases and 1,000 deaths.

A week later, Moderna began its own Phase 1 trial of the mRNA‑1469 vaccine in Canada, enrolling about 80 adults across three sites. The study, approved by Health Canada, aims to assess safety and immune response. Moderna’s effort is supported by CEPI, which has pledged up to $50 million for early testing and manufacturing, and the company plans to make at least 500,000 doses available to low‑ and middle‑income countries at access pricing if approved. Updated outbreak figures cite 3,748 confirmed cases and 1,657 deaths in the DRC, underscoring the urgent need for multiple vaccine candidates.

On 4 August 2026, the first volunteer in Moderna’s Canadian trial received the mRNA‑1469 dose in Truro, Nova Scotia, confirming the study’s launch at three locations—Truro, Halifax and Toronto. The trial proceeds alongside the Oxford vaccine effort, reflecting a rapid, multinational push to develop effective vaccines against the Bundibugyo Ebola strain amid a severe epidemic in Central Africa.

Claims

What the coverage asserts, and how well corroborated each claim is across sources.

[● 10 SOURCES] Health Canada cleared the early‑stage study. (Health Canada)
[● 10 SOURCES] The trial will enroll about 80 healthy adults at three sites in Canada. (Moderna/Health Canada)
[● 10 SOURCES] The World Health Organization and Africa CDC have declared the outbreak a public‑health emergency. (WHO & Africa CDC)
[● 5 SOURCES] Moderna began its first human trial of an experimental vaccine against Bundibugyo ebolavirus. (Moderna)
[● 5 SOURCES] The vaccine candidate is called mRNA-1469. (Moderna)
[● 5 SOURCES] CEPI has pledged up to $50 million to fund the vaccine’s early testing and manufacturing. (CEPI)
[● 5 SOURCES] The Bundibugyo outbreak in the Democratic Republic of Congo has 3,748 confirmed cases and 1,657 deaths as of Aug 1, according to U.S. CDC data. (U.S. CDC)
[● 5 SOURCES] Moderna plans to make at least 500,000 doses available to low‑ and middle‑income countries at access pricing if the vaccine is approved. (Moderna)

Timeline

about 7 hours ago

[HEALTH] 19 sources
Moderna launches Phase 1 Ebola vaccine trial in Canada
Moderna’s mRNA‑1469 Ebola vaccine begins a Health‑Canada‑approved Phase 1 trial in Canada, enrolling ~80 adults; CEPI funds $50 M, and 500k doses will be offered to low‑income nations if approved.
9 days ago

[HEALTH] 2 sources
Oxford Vaccine ChAdOx1 BDBV Administered to First Human Volunteer
Oxford’s ChAdOx1 BDBV Ebola vaccine was given to volunteer Ed Hunt, the first human test, targeting the Bundibugyo strain amid a DRC outbreak.

Sources

680news.com · battlefordsnow.com · bolnews.com · ca.sports.yahoo.com · castanet.net · dgabc.com.br · freemalaysiatoday.com · globaldiasporanews.com · kfgo.com · kitchener.citynews.ca · larongenow.com · narcity.com · news1130.com · panow.com · paparazzi.com.ar · stocktitan.net · winnipeg.citynews.ca · wkzo.com · wxerfm.com

This summary has been updated 1 time: see revision history